Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qu Feng Zhi Tong is a Traditional Chinese Medicine (TCM) hospital preparation developed by the First Affiliated Hospital of Harbin Medical University, specifically indicated for the treatment of knee osteoarthritis (KOA). Formulated to address the TCM syndrome of wind-cold-dampness (Bi syndrome), the preparation typically consists of a blend of herbal extracts including *Radix Angelicae Pubescentis*, *Radix Gentianae Macrophyllae*, and *Cortex Eucommiae*. Pharmacologically, Qu Feng Zhi Tong exerts anti-inflammatory and analgesic effects by inhibiting the production of pro-inflammatory cytokines such as Interleukin-1 beta (IL-1β) and Tumor Necrosis Factor (TNF). Additionally, it has been shown to modulate matrix metalloproteinases (MMPs), thereby reducing the degradation of articular cartilage and improving joint function in patients with degenerative joint diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qu Feng Zhi Tong.